Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma

NCT05233397 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT05233397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2022
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adamantinomatous craniopharyngioma, recurrent adamantinomatous craniopharyngioma